IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Advancements In Biopharmaceuticals: Promising Future In Medicine

Dr.Samson Raju. Cherukuri,
Lecturer in Zoology,
Department of Zoology,
Govt. Degree College, Puttur,TirupatiDt, AP, India.

Abstract: Recent advances in biopharmaceuticals promise a bright future for medicine by providing innovative solutions for disease treatment and prevention. These drugs are derived from living organisms and offer highly targeted therapies that are more precise and have fewer side effects. These advanced drugs closely resemble human proteins, thereby minimizing the risk of immune reactions. Biopharmaceuticals have revolutionized medical treatments with innovations such as monoclonal antibodies, gene therapies, and cultured cell-based therapies. The increasing number of FDA-approved biologics from 2015 to 2023 highlights their expanding role in treating a wide range of medical conditions. As research continues to progress, we can expect even more exciting developments in the field.

Introduction

Biopharmaceuticals, or biologics, are therapeutic agents produced from living cells or biological systems, in contrast to traditional drugs, which are chemically synthesized. While conventional pharmaceuticals are effective in treating various medical conditions, they come with limitations such as side effects, drug resistance, non-specific action and manufacturing challenges. Biopharmaceuticals, however, have transformed medical treatments by offering improved specificity, targeted mechanisms and fewer side effects, with potential for personalized therapies. They are developed through advanced biotechnological methods, including recombinant DNA and cell culture techniques and are designed to closely mimic human proteins, reducing the risk of immune reactions. Their adaptability enables innovative treatments for complex diseases, utilizing methods such as monoclonal antibodies and gene therapies. Biopharmaceuticals include a variety of therapies like vaccines, growth factors, and cytokines. Between 2015 and 2022, the U.S. Food and Drug Administration (FDA) approved 106 biologics, with a yearly breakdown of approvals ranging from 7 to 17. Some of these FDA-approved biologics are highlighted in this discussion.

Vaccines

Vaccines have revolutionized global public health between 2013 and 2023, with the World Health Organization (WHO) and the U.S. Food and Drug Administration (USFDA) approving several life-saving vaccines (1, 2). The COVID-19 pandemic has highlighted the importance of vaccines, with Pfizer-BioNTech, Moderna, Johnson & Johnson, and Sinovac developing effective vaccines that have significantly reduced the virus's spread and severity (3). Other notable approvals include the malaria vaccine (RTS,S/AS01 or Mosquirix), the first vaccine approved for preventing malaria, and the Ebola vaccine (Ervebo), providing protection against Ebola Zaire virus (4). Additionally, the Dengue vaccine (Dengvaxia) was approved for preventing dengue fever, and therapeutic vaccines like the Human papillomavirus vaccine (Gardasil 9) have reduced cancer rates, showcasing the power of vaccines in disease prevention and control.

Erythropoietins (EPOs)

Advances in erythropoietin treatments have transformed anemia management in patients with chronic kidney disease (CKD) and those undergoing chemotherapy (5). Biosimilars of epoetinalfa, such as Retacrit, and long-acting agents like darbepoetinalfa (Aranesp) and epoetin beta (Mircera) have improved treatment outcomes, reducing dosing frequency, enhancing patient compliance, minimizing transfusion requirements, and mitigating transfusion-associated risks (6). These advancements have significantly improved the quality of life for patients with anemia, enabling them to manage their condition more effectively.

Clotting Factors

Novel clotting factors have revolutionized hemophilia management, with key approvals including extended half-life products like efmoroctocogalfa (Eloctate) for hemophilia A and eftrenonacogalfa (Alprolix) for hemophilia B (7). Gene therapy, such as valoctocogeneroxaparvovec (Roctavian) for hemophilia A, has also been approved, offering new hope for patients with this debilitating condition (8). These advancements have reduced bleeding episodes, minimized hospitalizations, improved life expectancy, and enhanced quality of life for patients with hemophilia.

Cytokines

Cytokine therapies have expanded treatment options for cancer and autoimmune diseases, offering new possibilities for patients with these conditions (9). Peginterferon beta-1a (Plegridy) has been approved for multiple sclerosis, while interleukin-based therapies like IL-17 inhibitors (Secukinumab) and IL-23 inhibitors (Guselkumab) have been developed to treat psoriasis and psoriatic arthritis (10). These treatments have improved patient outcomes, reduced long-term complications, and enhanced quality of life for patients with these conditions.

Interferons

Interferon therapies have enhanced treatment strategies for viral infections and cancers, offering new avenues for treatment (11). Peginterferon beta-1a (Plegridy) has been approved for multiple sclerosis, while interferon gamma-1b (Actimmune) has been used for chronic granulomatous disease and severe malignant osteopetrosis (12). These therapies have improved treatment outcomes, reduced disease severity, and enhanced patient quality of life.

Growth Hormones

Advances in growth hormone therapies have transformed treatment for growth disorders, offering new possibilities for patients with these conditions (13). Somapacitan (Sogroya), a once-weekly injectable growth hormone, and somatrogon (Ngenla), a recombinant human growth hormone with longer-acting effects, have been approved, enhancing patient compliance, improving quality of life, supporting normal growth and development in children, and addressing metabolic issues in adults (14).

Enzyme replacement therapies (ERTs)

Enzyme replacement therapies (ERTs) have expanded treatment options for rare genetic and metabolic disorders, including lysosomal storage diseases (15). Sebelipasealfa (Kanuma) has been approved for lysosomal acid lipase deficiency, while cerliponasealfa (Brineura) has been approved for neuronal ceroidlipofuscinosis type 2 (CLN2) disease (16). These therapies address underlying enzyme deficiencies, improving patient outcomes and quality of life for patients with these rare conditions.

Fusion Proteins

New fusion proteins have expanded therapeutic options for autoimmune diseases, cancers, and rare genetic disorders, offering new hope for patients with these conditions (17). Efmoroctocogalfa (Eloctate) has been approved for hemophilia A, while emicizumab (Hemlibra) has been approved for hemophilia A. Romiplostim (Nplate) has been instrumental in treating chronic immune thrombocytopenia (ITP), showcasing the potential of fusion proteins in treating complex diseases (18).

Conclusion

In conclusion, biopharmaceuticals face development challenges, but the future holds promise. Emerging trends include personalized medicine, gene and cell therapies, and equitable distribution of innovations. The WHO emphasizes accessibility and healthcare equity, ensuring these therapies reach underserved populations, and ultimately improving global health outcomes.

References:

1. US Food and Drug Administration. (n.d.).Biological Product Definitions.https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf

2. US Food and Drug Administration. (n.d.).Biological Approvals by Year. https://www.fda.gov/vaccines-blood-biologics/development-approval-process cber/biological-approvals-year

3. Excler, J. L., Saville, M., Berkley, S., & Kim, J. H. (2021). Vaccine development for emerging infectious diseases. *Nature medicine*, *27*(4), 591-600.

4. Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature Reviews Drug Discovery, 13(9), 655-672.

5. US Food and Drug Administration.Information on Erythropoiesis-Stimulating Agents (ESA) Epoetinalfa (marketed as Procrit, Epogen), Darbepoetinalfa (marketed as Aranesp). Retrieved from (https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-epogenprocrit-epoetin-alfa)

6. Jelkmann, W. (2022). Erythropoiesis-Stimulating Agents: A Review of Their Use in Anemia Management. Journal of Clinical Pharmacology, 62(5), 631-643.

7. Dhillon, S. (2012). Octocogalfa, antihaemophilic factor (recombinant), plasma/albumin-free method (Advate): a review of its use in the management of patients with haemophilia A. Drugs, 72(7), 987-1007.

8. US Food and Drug Administration. (2022). FDA Approves New Treatment for Hemophilia A. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adultsseverehemophilia#:~:text=Today%2C%20the%20U.S.%20Food%20and,by%20an%20FD%2Dapproved%20test.

9. Peginterferon Alfa.https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf

10. Singh, S., et al. (2021). Cytokine-Based Therapies in Autoimmune Diseases: A Review. Journal of Clinical Immunology, 41(5), 931-943.

11. Food and Drug Administration. Orencia® (abatacept). Rockville, MD: U.S. Food and Drug Administration; 2005. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/125118lb l.pdf

12. World Health Organization. (2021). Interferons in the Treatment of Multiple Sclerosis. WHO Drug Information, Volume 35, No. 2.

13. Clinical Review Report - https://www.cadth.ca/sites/default/files/cdr/clinical/SR0333_GenotropinGHD-P_CL_Report_e.pdf

14. Lopez-Siguero, J. P., et al. (2022). Long-Acting Growth Hormone Preparations: A Review of Their Pharmacology and Clinical Use. Hormone Research in Paediatrics, 93(3), 149-158.

15. Jameson, E., Jones, S., &Remmington, T. (2019). Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I. Cochrane Database of Systematic Reviews, 6(6), CD009354.

16. Mistry, P. K., et al. (2021). Enzyme Replacement Therapy for Lysosomal Storage Diseases: A Review. Journal of Inherited Metabolic Disease, 44(2), 257-269.

17. Kesik-Brodacka, M. (2018). Progress in biopharmaceutical development. Biotechnology and Applied Biochemistry, 65(3), 306-322.

18. Wang, W., et al. (2022). Fusion Proteins in Biopharmaceutical Development: A Review. BioDrugs, 36(2), 155-167.